InsidersTradesSigma
Follow the Fennec Pharmaceuticals INC. stock price and the full management transaction log of the company, a listed issuer based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Fennec Pharmaceuticals INC. has recorded 209 public disclosures. Market capitalisation: €430.3m. The latest transaction was reported on 8 September 2026 (10 - Acquisition or disposition in the public market). Among the most active insiders: Raykov Rosty. All data is accessible without an account.
209
Insider Decl.
n/a
Thresholds
€6,242
3 ops.
Buy Volume
€11m
42 ops.
Sell Volume
50Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 22,254 of 29,062 companies
33.3
score / 100
Value27
Quality39
FCF yld-2.9%
Earn yld-2.3%
EV/EBITDA·
ROE-19%
Gross mgn92%
Net mgn-22%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 8 September 2026
Declarations209 total
1,703 sharesCommon SharesTSXSEDI:4774703
Canonical exit: 3 Dec 2026 (T+90)
1,159 sharesCommon SharesTSXSEDI:4774700
Canonical exit: 3 Dec 2026 (T+90)
168 sharesCommon SharesTSXSEDI:4774699
Canonical exit: 3 Dec 2026 (T+90)
12,000 shares@ CA$12.18Common SharesTSXSEDI:4774698
Canonical exit: 3 Dec 2026 (T+90)
168 sharesCommon SharesTSXSEDI:4774696
Canonical exit: 3 Dec 2026 (T+90)
156 sharesCommon SharesTSXSEDI:4774694
Canonical exit: 3 Dec 2026 (T+90)
2,778 shares0Common sharesSEC:0001468316-26-000023:0
10,000 shares@ US$12.110.028% mcap5.2% of flowCommon sharesSEC:0001468316-26-000023:1
12,000 shares@ US$12.18080.034% mcap100.0% of flowCommonSEC144:0001950047-26-008849
1,703 shares0Common sharesSEC:0001468308-26-000030:0
156 shares0Common sharesSEC:0002043411-26-000014:0
168 shares0Common SharesSEC:0002043317-26-000012:0
1,159 shares0Common SharesSEC:0001926254-26-000014:0
168 shares0Common SharesSEC:0002043395-26-000012:0
12,000 shares@ US$12.180.034% mcap100.0% of flowCommon SharesSEC:0002043395-26-000012:1
21,928 shares@ CA$5.10Common SharesTSXSEDI:4770042
Canonical exit: 26 Nov 2026 (T+90)
21,928 shares@ CA$5.100.019% mcap8.2% of flowOptionsTSXSEDI:4770040
Canonical exit: 26 Nov 2026 (T+90)
106,844 shares@ CA$11.790.21% mcap100.0% of flowCommon SharesTSXSEDI:4769718
Canonical exit: 25 Nov 2026 (T+90)
75,000 shares@ US$11.780.21% mcap45.2% of flowCommon sharesSEC:0001468308-26-000028:0
21,928 shares@ US$5.100.026% mcap5.7% of flowCommon sharesSEC:0001468308-26-000028:1
75,000 shares@ US$11.78530.21% mcap100.0% of flowCommonSEC144:0001950047-26-008768
1,703 sharesCommon SharesTSXSEDI:4758147
Canonical exit: 1 Nov 2026 (T+90)
168 sharesCommon SharesTSXSEDI:4758131
Canonical exit: 1 Nov 2026 (T+90)
1,159 sharesCommon SharesTSXSEDI:4758124
Canonical exit: 1 Nov 2026 (T+90)
156 sharesCommon SharesTSXSEDI:4758112
Canonical exit: 1 Nov 2026 (T+90)
25 of 209 declarations
关于 Fennec Pharmaceuticals INC.
Fennec Pharmaceuticals Inc. 是一家在美国纳斯达克（股票代码：FENC）上市的专业制药公司。该公司总部位于北卡罗来纳州三角研究园，专注于一个高度特定的肿瘤支持性护理利基市场：减少局部非转移性实体瘤儿科患者顺铂诱导的耳毒性。其核心资产是 PEDMARK®（硫代硫酸钠注射液），该产品于2022年9月获得 FDA 批准，并于2022年10月开始在美国商业上市。在美国以外，同一产品以 PEDMARQSI® 的名称销售，已在欧洲和英国获得批准，这使得 Fennec 拥有比其国内业务范围更广阔的国际发展空间。([investors.fennecpharma.com](https://investors.fennecpharma.com/?utm_source=openai)) 从公司历史的角度来看，Fennec 最初在不列颠哥伦比亚省注册成立，名为 Adherex Technologies Inc.，并于2014年更名为 Fennec Pharmaceuticals Inc.。这一演变对投资者很重要，因为它反映了公司从早期开发活动向以一种领先品牌疗法为核心的商业化阶段模式的转变。如今，该公司的业务几乎完全集中在美国市场的 PEDMARK 上，并由 Fennec HEARS™ 患者支持平台提供支持，该平台旨在帮助家庭和医疗服务提供者解决获取、报销和治疗物流问题。([sec.gov](https://www.sec.gov/Archives/edgar/data/1211583/000155837025003710/fencf-20241231x10k.htm?utm_source=openai)) 在竞争方面，Fennec 是一家专注的专业公司，而非一家广泛的肿瘤公司。它并非围绕着庞大多元化的产品线而建立；相反，其投资案例取决于单一差异化产品在明确界定的医院环境中的临床和商业应用。这既带来了集中风险，也带来了战略清晰性。该公司的护城河与监管批准、预防接受顺铂治疗儿童听力损失的临床相关性以及在肿瘤护理路径中扩大使用的能力相关。在国际上，Fennec 通过许可而非直接商业建设来扩大其业务范围：2024年3月，它与 Norgine 签署了一项独家协议，在欧洲、澳大利亚和新西兰商业化 PEDMARQSI，这扩大了地理覆盖范围，同时限制了资本密集度。([sec.gov](https://www.sec.gov/Archives/edgar/data/1211583/000155837025003710/fencf-20241231x10k.htm?utm_source=openai)) 近期发展态势良好。2026年3月，Fennec 报告了2025年全年创纪录的净产品销售额，并描述了2025年持续的季度环比增长。2025年，该公司还披露了一项由研究者发起的在日本评估 PEDMARK 治疗顺铂诱导听力损失的研究的积极顶线结果，并宣布与 City of Hope 和 Tampa General Hospital Cancer Institute 等美国领先癌症机构开展额外的研究合作。对于投资者而言，这些更新表明该公司正在从在美国的首次商业化迈向更广泛的证据生成和潜在的标签/市场扩张，同时仍保留了小型单一产品制药企业的风险特征。([investors.fennecpharma.com](https://investors.fennecpharma.com/news-releases/news-release-details/fennec-pharmaceuticals-reports-fourth-quarter-and-full-year-2025?utm_source=openai))
